PURPOSE OF REVIEW: This article discusses the recent advances in the diagnosis and treatment of Alzheimer disease (AD). RECENT FINDINGS: In recent years, significant advances have been made in the fields of genetics, neuroimaging, clinical diagnosis, and staging of AD. One of the most important recent advances in AD is our ability to visualize amyloid pathology in the living human brain. The newly revised criteria for diagnosis of AD dementia embrace the use for biomarkers as supportive evidence for the underlying pathology. Guidelines for the responsible use of amyloid positron emission tomography (PET) have been developed, and the clinical and economic implications of amyloid PET imaging are actively being explored. SUMMARY: Our improved understanding of the clinical onset, progression, neuroimaging, pathologic features, genetics, and other risk factors for AD impacts the approaches to clinical diagnosis and future therapeutic interventions.
PURPOSE OF REVIEW: This article discusses the recent advances in the diagnosis and treatment of Alzheimer disease (AD). RECENT FINDINGS: In recent years, significant advances have been made in the fields of genetics, neuroimaging, clinical diagnosis, and staging of AD. One of the most important recent advances in AD is our ability to visualize amyloid pathology in the living human brain. The newly revised criteria for diagnosis of AD dementia embrace the use for biomarkers as supportive evidence for the underlying pathology. Guidelines for the responsible use of amyloid positron emission tomography (PET) have been developed, and the clinical and economic implications of amyloid PET imaging are actively being explored. SUMMARY: Our improved understanding of the clinical onset, progression, neuroimaging, pathologic features, genetics, and other risk factors for AD impacts the approaches to clinical diagnosis and future therapeutic interventions.
Authors: K Buerger; M Ewers; N Andreasen; R Zinkowski; K Ishiguro; E Vanmechelen; S J Teipel; C Graz; K Blennow; H Hampel Journal: Neurology Date: 2005-11-08 Impact factor: 9.910
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Thomas G Beach; Julie A Schneider; Lucia I Sue; Geidy Serrano; Brittany N Dugger; Sarah E Monsell; Walter Kukull Journal: J Neuropathol Exp Neurol Date: 2014-10 Impact factor: 3.685
Authors: K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel Journal: Neurology Date: 2002-08-27 Impact factor: 9.910
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Elin Engdahl; Maarten D M van Schijndel; Dimitrios Voulgaris; Michela Di Criscio; Kerry A Ramsbottom; Daniel J Rigden; Anna Herland; Joëlle Rüegg Journal: Int J Mol Sci Date: 2021-05-24 Impact factor: 5.923
Authors: Jorge Oliveira; Pedro Gamito; Teresa Souto; Rita Conde; Maria Ferreira; Tatiana Corotnean; Adriano Fernandes; Henrique Silva; Teresa Neto Journal: Int J Environ Res Public Health Date: 2021-05-16 Impact factor: 3.390